Royal Bank of Canada Raises Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,260.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by Royal Bank of Canada from $1,252.00 to $1,260.00 in a research note published on Friday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on REGN. Cantor Fitzgerald restated a neutral rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 16th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an overweight rating in a research note on Friday, August 2nd. Leerink Partners reiterated a market perform rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets restated an outperform rating and set a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Truist Financial reaffirmed a buy rating and issued a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $1,119.00.

Regeneron Pharmaceuticals Stock Down 0.2 %

NASDAQ REGN opened at $1,012.82 on Friday. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The stock has a market cap of $111.65 billion, a PE ratio of 29.92, a PEG ratio of 3.55 and a beta of 0.12. The firm has a 50-day simple moving average of $1,125.65 and a 200 day simple moving average of $1,037.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $8.79 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,033 shares of company stock valued at $9,399,345 over the last quarter. Corporate insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $26,000. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.